Literature DB >> 15270848

Prevention of experimental autoimmune encephalomyelitis in DA rats by grafting primary skin fibroblasts engineered to express transforming growth factor-beta1.

T Zargarova1, O Kulakova, V Prassolov, T Zharmukhamedova, V Tsyganova, V Turobov, D Ivanov, M Parfenov, M Sudomoina, Y Chernajovsky, O Favorova.   

Abstract

To determine whether primary fibroblasts producing latent transforming growth factor beta1 (TGF-beta1) are capable of down-regulating experimental autoimmune encephalomyelitis (EAE), a retroviral vector TGF-beta1-pBabe-neo (-5'UTR) was used for efficient gene transfer into primary skin fibroblasts of DA rats. After heat activation, conditioned medium from the transduced fibroblasts was found to inhibit significantly in vitro proliferation of lymphocytes from lymph nodes of DA rats with EAE. Intraperitoneal administration of TGF-beta1-transduced fibroblasts into DA rats during the priming phase of EAE resulted in a significant reduction in mortality and in the mean clinical and EAE scores versus the control immunized animals treated with non-transduced fibroblasts.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15270848      PMCID: PMC1809117          DOI: 10.1111/j.1365-2249.2004.02539.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  44 in total

1.  Cytokine gene therapy in experimental allergic encephalomyelitis by injection of plasmid DNA-cationic liposome complex into the central nervous system.

Authors:  J L Croxford; K Triantaphyllopoulos; O L Podhajcer; M Feldmann; D Baker; Y Chernajovsky
Journal:  J Immunol       Date:  1998-05-15       Impact factor: 5.422

2.  Genetic influence on disease course and cytokine response in relapsing experimental allergic encephalomyelitis.

Authors:  P Kjellén; S Issazadeh; T Olsson; R Holmdahl
Journal:  Int Immunol       Date:  1998-03       Impact factor: 4.823

3.  TGF-beta is elevated in the CSF of patients with severe traumatic brain injuries and parallels blood-brain barrier function.

Authors:  M C Morganti-Kossmann; V H Hans; P M Lenzlinger; R Dubs; E Ludwig; O Trentz; T Kossmann
Journal:  J Neurotrauma       Date:  1999-07       Impact factor: 5.269

4.  Transforming growth factor-beta 1 induces antigen-specific unresponsiveness in naive T cells.

Authors:  K M Gilbert; M Thoman; K Bauche; T Pham; W O Weigle
Journal:  Immunol Invest       Date:  1997-06       Impact factor: 3.657

5.  TGF-beta1 inhibits protracted-relapsing experimental autoimmune encephalomyelitis by activating dendritic cells.

Authors:  Y X Jin; L Y Xu; H Guo; M Ishikawa; H Link; B G Xiao
Journal:  J Autoimmun       Date:  2000-05       Impact factor: 7.094

6.  Immunopharmacological studies on experimental allergic encephalomyelitis in DA rats.

Authors:  H Nagai; M Goto; H Kamada; K Boda; K Kitagaki; Y Takaoka
Journal:  Gen Pharmacol       Date:  1998-02

7.  Polygenic control of experimental allergic encephalomyelitis in Biozzi ABH and BALB/c mice.

Authors:  J L Croxford; J K O'Neill; D Baker
Journal:  J Neuroimmunol       Date:  1997-04       Impact factor: 3.478

8.  TGFbeta1 and TGFbeta2 concentrations are elevated in Parkinson's disease in ventricular cerebrospinal fluid.

Authors:  M P Vawter; O Dillon-Carter; W W Tourtellotte; P Carvey; W J Freed
Journal:  Exp Neurol       Date:  1996-12       Impact factor: 5.330

9.  Gene therapy in allergic encephalomyelitis using myelin basic protein-specific T cells engineered to express latent transforming growth factor-beta1.

Authors:  L Z Chen; G M Hochwald; C Huang; G Dakin; H Tao; C Cheng; W J Simmons; G Dranoff; G J Thorbecke
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-13       Impact factor: 11.205

10.  Gene therapy for chronic relapsing experimental allergic encephalomyelitis using cells expressing a novel soluble p75 dimeric TNF receptor.

Authors:  J L Croxford; K A Triantaphyllopoulos; R M Neve; M Feldmann; Y Chernajovsky; D Baker
Journal:  J Immunol       Date:  2000-03-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.